News Dainippon Sumitomo Pharma America Announces FDA Acceptance of Lurasidone New Drug Application for Treatment of Schizophrenia
News Sepracor Announces New Management Changes and Plans for Merger with Dainippon Sumitomo Pharma America
News FDA Extends PDUFA Action Date for STEDESA™ New Drug Application
News Dainippon Sumitomo Pharma America Announces the NDA Submission of Lurasidone to the FDA for the Treatment of Schizophrenia